Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment

Journal of Clinical Pharmacology

Volumn 45, Issue 11, 2005, Pages 1259-1267

  Turncliff, Ryan Z ^a   Dunbar, Joi L ^a   Dong, Qunming ^a   Silverman, Bernard L ^a   Ehrich, Elliot W ^a   Dilzer, Stacy C ^b   Lasseter, Kenneth C ^b  

^a ALKERMES INC   (United States)

^b SFBC International   (United States)

Author keywords

Alcoholism; Hepatic impairment; LA NTX; Long acting; Naltrexone

Indexed keywords

DRUG METABOLITE; NALTREXOL; NALTREXONE;

ADULT; AGED; ALCOHOLISM; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; EXTENDED RELEASE FORMULATION; FEMALE; HEADACHE; HUMAN; LIVER DISEASE; MALE; PATIENT CODING; SLOW DRUG RELEASE;

ADULT; AGED; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS;

EID: 27244455239     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005280199     Document Type: Article

References (29)

1. Murray CJ, Lopez AD. Global and regional descriptive epidemiology of disability: incidence, prevalence, health expectancies, and years lived with disability. In: Murray CJ, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston: Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996;201-246.
2. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend. 2004;74:223-234.
3. O'Connor PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med. 1998;338:592-602.
4. Fleming MF, Barry KL, Manwell LB, Johnson K, London R. Brief physician advice for problem alcohol drinkers: a randomized controlled trial in community-based primary care practices. JAMA. 1997;277:1039-1045.
5. McGinnis JM, Foege WH. Mortality and morbidity attributable to use of addictive substances in the United States. Proc Assoc Am Physicians. 1999;111:109-118.
6. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881-887.
7. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
8. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54:737-742.
9. Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction. 2004;99:1382-1392.
10. Dean RL. The preclinical development of medisorb naltrexone, a once a month long acting injection, for the treatment of alcohol dependence. Front Biosci. 2005;10:643-655.
11. Brouwer KLR, Dukes GE, Powell JR. Influence of liver function on drug disposition. In: Evans WE, Schentag JL, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, Wash: Applied Therapeutics; 1992:6-1-6-59.
12. NIAAA Alcohol Alert No. 19.
13. Wall ME, Brine DR, Perez-Reyes M. Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos. 1981;9:369-375.
14. Cone EJ, Gorodetzky CW, Yeh SY. The urinary excretion profile of naltrexone and metabolites in man. Drug Metab Dispos. 1974;2:506-512.
15. Meyer MC, Stiaughn AB, Lo MW, Schary WL, Whitaey CC. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry. 1984;45:15-19.
16. ReVia (naltrexone hydrochloride tablets) [package insert]. Wilmington, Del: DuPont Pharma; 1998.
17. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. 2002;27:596-606.
18. Porter SJ, Somogyi AA, White JM. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. Addict Biol. 2002;7:219-225.
19. Bertolotti M, Ferrari A, Vitale G, et al. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J Hepatol. 1997;27:505-511.
20. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-1625.
21. Dunbar JD, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single and multiple dose pharmacokinetics of long-acting naltrexone. Alcoholism: Clinical and Experimental Research. Submitted for publication.
22. Silber BM, Bialer M, Yacobi A. Pharmacokinetic/ pharmacodynamic basis of controlled drug delivery. In: Robinson JR, Lee VH, eds. Controlled Drug Delivery Fundamentals and Applications. 2nd ed. New York: Marcel Dekker; 1987:213-251.
23. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004;5:157-167.
24. Ohara H, Miyabe Y, Deyashiki Y, Matsuura K, Hara A. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol. 1995;50:221-227.
25. Porter SJ, Somogyi AA, White JM. Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol. 2000;50:465-471.
26. Breyer-Pfaff U, Nill K. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J Pharm Pharmacol. 2004;56:1601-1606.
27. Ludden TM, Malspeis L, Baggot JD, Sokoloski TD, Frank SG, Reuning RH. Tritiated naltrexone binding in plasma from several species and tissue distribution in mice. J Pharm Sci. 1976;65:712-716.
28. Yoon YH, Yi HY, Grant BF, Dufour MC. Surveillance Report #57: Liver Cirrhosis Mortality in the United States, 1970-98. Bethesda, Md: National Institute on Alcohol Abuse and Alcoholism; 2001.
29. Mammen EF. Coagulation defects in liver disease. Med Clin North Am. 1994;78:545-554.